Core Laboratories financials
$9.71−3.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $124.6M | $121.8M | $138.3M | $134.5M | $130.2M | $123.6M | $129.2M | $134.4M | $130.6M | $129.6M | $128.2M | $125.3M |
| Gross profit | $23.2M | $19.7M | $28.7M | $29.6M | $26.5M | $24.1M | $23.0M | $27.6M | $27.6M | $25.0M | $26.7M | $28.7M |
| Gross margin | 18.6% | 16.2% | 20.8% | 22.0% | 20.3% | 19.5% | 17.8% | 20.5% | 21.2% | 19.3% | 20.8% | 22.9% |
| Operating income | $9.2M | $1.9M | $15.8M | $20.9M | $15.3M | $4.4M | $14.2M | $19.8M | $16.0M | $8.6M | $14.6M | $14.7M |
| Net income | $6.0M | -$789.0K | $4.4M | $14.5M | $10.6M | -$154.0K | $6.7M | $12.0M | $9.0M | $3.2M | $2.2M | $9.3M |
| Net margin | 4.8% | −0.6% | 3.2% | 10.8% | 8.2% | −0.1% | 5.2% | 8.9% | 6.9% | 2.5% | 1.7% | 7.4% |
| Diluted EPS | $0.13 | $-0.02 | $0.09 | $0.31 | $0.22 | $0.00 | $0.14 | $0.25 | $0.19 | $0.07 | $0.05 | $0.19 |
| EBITDA | $13.0M | $5.7M | $19.5M | $24.5M | $19.0M | $8.1M | $17.8M | $23.5M | $19.8M | $12.4M | $14.6M | $18.6M |
| Operating cash flow | $7.8M | $4.0M | $7.9M | $8.5M | $13.9M | $6.7M | $20.6M | $13.1M | $17.1M | $5.5M | $19.4M | -$212.0K |
| Free cash flow | $2.0M | -$926.0K | $1.6M | $8.1M | $9.6M | $3.1M | $16.2M | $10.4M | $14.3M | $2.5M | $16.7M | -$3.7M |
| Diluted shares | 46.9M | 46.1M | 46.9M | 47.1M | 47.4M | 46.8M | 47.5M | 47.8M | 47.7M | 47.7M | 47.5M | 47.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.7M | $22.8M | $22.7M | $25.6M | $31.2M | $22.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $113.9M | $114.5M | $110.3M | $114.1M | $124.6M | $124.4M |
| Total assets | $586.8M | $587.7M | $584.0M | $591.4M | $602.1M | $591.5M |
| Total liabilities | $308.0M | $312.6M | $311.8M | $314.0M | $334.8M | $332.2M |
| Shareholders' equity | $278.8M | $275.1M | $272.2M | $277.4M | $267.3M | $259.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology